Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parents/Legally Acceptable Representative (LARs) can and will comply with the requirements of the protocol.~* A male or female between, and including, 6 and 35 months of age at the time of first vaccination; children are eligible regardless of history of influenza vaccination.~* Written informed consent obtained from the parent(s) /LAR(s) of the subject.~* Subjects in stable health as determined by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Participation in a previous FLU-D-QIV-004 study (115345) cohort.~* Child in care.~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Prior receipt of any influenza vaccine within 6 months preceding the first dose of study vaccine, or planned use of such vaccines during the study period.~* Children with underlying illness who are at risk of complications of influenza and for whom yearly (seasonal) influenza vaccination is recommended in their respective country.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (including HIV), based on medical history and physical examination.~* Chronic administration of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids are allowed.~* Administration of immunoglobulins and/ or any blood products within 3 months preceding the first dose of study vaccine or planned administration during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines, non-influenza vaccine comparators and latex; a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous vaccination.~* Any contraindication to intramuscular injection.~* Acute disease and/or fever at the time of enrolment.~* Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.~* Additional criteria for children ≥ 12 months of age:~  * Prior receipt of any licensed varicella vaccine\* or any licensed hepatitis A vaccine or planned use of these vaccines during the study period. Other routine registered childhood vaccinations are permitted.~    \* For countries with varicella vaccine administered as 2-dose schedule, prior receipt of a single dose of a varicella vaccine is allowed if administered at least 2 weeks before the first study vaccination.~ * Any history of hepatitis A or varicella diseases.~* Additional criteria for children 6 - 11 months of age in countries without universal mass vaccination recommendation for pneumococcal vaccine:~  * Prior receipt of any pneumococcal conjugated vaccine or planned use of this vaccine during the study period. Other routine registered childhood vaccinations are permitted.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- D-QIV (Type: EXPERIMENTAL): Subjects received 1 or 2 doses of candidate influenza Influsplit™ Tetra vaccine (GSK2321138A).
- Control (Type: ACTIVE_COMPARATOR): In function of their age and D-QIV-vaccine status, subjects received Prevenar 13® or Havrix® Junior and possibly a varicella vaccine (Varilrix® or Varivax/ProVarivax ®).

Based on this trial design, predict the completion outcome and termination type (if applicable).